Background {#Sec1}
==========

Inflammation is a non-specific response to insults to the body. A five-fold increase in inflammation, as measured by CRP levels, occurs over the course of normal pregnancy \[[@CR1]\], and the fetal impact is unknown. Elevated inflammation beyond the physiological increase during pregnancy has been implicated as a mediator in the associations of a myriad of prenatal exposures (e.g., infectious disease \[[@CR2]\], maternal obesity \[[@CR3], [@CR4]\], maternal stress \[[@CR5]\], and air pollution \[[@CR6]\]) with offspring health. Moreover, maternal inflammation is linked with preterm birth \[[@CR7], [@CR8]\], preeclampsia \[[@CR9], [@CR10]\], and childhood asthma/allergies \[[@CR11]--[@CR14]\]. Also, women with chronic inflammatory diseases such as rheumatoid arthritis have lower weight babies \[[@CR15]\]. Developmental programming studies suggest that prenatal exposures could alter long-term offspring health through epigenetic changes, often effected via DNA methylation. DNA methylation is one epigenetic modification that has become frequently studied due to the availability of reliable and affordable technologies.

C-reactive protein (CRP) is a cytokine routinely used to measure inflammation. CRP is an acute phase reactant produced by the liver, and serum levels can increase 3000-fold within a short amount of time as part of innate immunity \[[@CR16]\]. Its plasma half-life is about 18 h but in the acute phase may only be 75 min \[[@CR16]\]. Rapid increase in CRP is associated with infections rather than prenatal exposures or systemic inflammation. While many cytokines including interleukins and interferons are part of the inflammatory response, CRP is most often studied due to reliable assay and clinical use as a global marker of systemic chronic inflammation. In adults, circulating CRP has been cross-sectionally associated with altered DNA methylation patterns in white blood cells in a meta-analysis of epigenome-wide studies with data from 8863 Europeans and 4111 African Americans \[[@CR17]\]. Moreover, evidence from a longitudinal study of over 100 adults shows DNA methylation changes specific to CRP levels measured 10 years prior, suggesting lasting influence of inflammation on DNA methylation \[[@CR18]\]. However, it is unclear whether CRP throughout pregnancy has similar effects on newborn methylation, and whether the timing of the exposure at different gestational ages, including at delivery, matters. Longitudinal analyses of CRP during pregnancy, therefore, could be informative in understanding the role of inflammation on newborn methylation. Decreasing maternal inflammation could also be another way to demonstrate a causal role, and low dose aspirin use may decrease maternal CRP \[[@CR19]\], which may in turn alter newborn methylation.

We aimed to comprehensively identify newborn DNA methylation differences associated with prenatal CRP exposure. In the Effects of Aspirin in Gestation and Reproduction (EAGeR) study, high-sensitivity CRP levels were measured longitudinally in maternal serum at three time points during pregnancy and in cord blood at delivery. Newborn DNA methylation was assessed in cord blood obtained at delivery. In addition, as part of the Pregnancy And Childhood Epigenetic (PACE) consortium \[[@CR20]\], maternal CRP levels measured in the first trimester and DNA methylation in cord blood were available from three international pregnancy cohorts.

Results {#Sec2}
=======

Women in EAGeR had an average pre-pregnancy BMI of 25.2 kg/m^2^, predominantly did not smoke, and 43% had household income levels above \$100,000 (Table [1](#Tab1){ref-type="table"}). Levels of maternal and cord blood CRP are provided in Table [2](#Tab2){ref-type="table"}. No significant associations between maternal CRP concentrations during pregnancy were found regardless of gestational age at measure in EAGeR (i.e., in first, second, or third trimester) in crude models adjusted for covariates (i.e., Model 1: maternal age, smoking, income, pre-pregnancy BMI, plate) or in two models additionally adjusting for cell type distribution using two different cord blood reference panels (i.e., Model 2, Bakulski \[[@CR21]\]; Model 3, Gervin \[[@CR22]\] ([Supplemental Tables A--C](#MOESM1){ref-type="media"} in the online repository, Figshare)). In sensitivity analysis, we repeated all analyses without exclusion of CRP \>10 mg/dl so as to not exclude acute infections but found no associations aside from one CpG with third trimester CRP levels which was not in a known gene region (cg14503868; beta = − 0.02, FDR *p* = 0.01; located in Chr 9, position 128504605, closest to *PBX3*) (See [Supplemental Tables A4, B4, C4](#MOESM1){ref-type="media"} on Figshare). Table 1EAGeR maternal and infant characteristicsPlaceboLow-dose aspirin*n* = 358*n*/mean%/SD*n*/mean%/SD*n*/mean%/SD*p* valueMaternal age (years)28.24.428.24.628.24.30.91High school or more32089%15791%16388%0.27Randomized to aspirin18552%00185100%n/aSmoking102.842.363.20.30≥ \$100,000 income15243%6839%8445%0.65Married34697%16394%18399%0.03BMI (kg/m^2^)25.25.625.86.024.65.10.05Female baby17950%9354%8646%0.20Gestational age (wk)38.91.638.91.7338.91.370.98Birth weight (g)3347.0475.03358.3514.53336.6436.20.67Missing (*n*), BMI (3), smoking (2)Table 2Distribution of CRP concentrationsStudyTiming of measure*n*GA (week) of measureMean CRPSD CRPMedian CRPCRP range (min--max)EAGeRPreconception350n/a1.71.80.90.11--9.96EAGeR1st trimester3228.83.02.42.30.15--9.86EAGeR2nd trimester30420.94.22.43.70.15--10EAGeR3rd trimester32036.53.82.23.40.17--9.94EAGeRAUC log (CRP)359n/a46.214.443.813.98--97.83EAGeRDelivery CRP358Delivery0.20.40.10--5.67INMA1st trimester26613.54.42.14.02.00--9.38PREDO1st trimester24213.03.72.43.10.23--9.78Generation R1st trimester77313.13.92.53.30.3--10.0

Similarly, in the meta-analysis with three PACE cohorts for first trimester CRP measures, no significant associations were found. Table [3](#Tab3){ref-type="table"} lists the top 5 associations (all FDR *p* \> 0.05) in the meta-analysis and the direction of association from each cohort. Supplemental Table 1 provides characteristics of the participants in the other cohorts, and Supplemental Table 2 provides information on the genomic inflation of the various models run from each study. Table 3Meta-analysis of first trimester CRP and newborn methylation in four cohortsCpG SiteEffectSE*p* value\*Direction\*\*Het. *p* valueChr: positioncg198586710.00418.00E−041.21E-06++?+0.838: 130951373cg06320401− 0.00920.00191.50E-06\-\-\--0.741: 48176755cg22649187− 0.00690.00153.56E-06\-\-\--0.8811: 48176755cg04747517− 0.00225.00E−043.89E-06\-\-\--0.733: 169755595cg05986933− 0.00429.00E−044.11E-06\-\-\--0.842: 43020457*SE* standard error, *Het* heterogeneity, *chr* chromosome\*All FDR *p* values \< 0.5 (non-significant) and were adjusted for maternal age, race (as applicable), socioeconomic income (by education, income, or other cohort specific factors), maternal BMI and smoking, and cell type distribution \[[@CR21]\] (Model 2)\*\*Direction of associations for each cohort in the following order: GenR, PREDO, INMA, EAGeR; the "?" is due this CpG being excluded from analysis in INMA after data cleaning steps

One association with newborn methylation was identified in additional analyses performed in EAGeR to evaluate whether cumulative inflammation over pregnancy (as estimated by the area under the curve of CRP measured in gestational weeks 8--36) was associated with DNA methylation in offspring ([Supplemental Tables D1-3](#MOESM1){ref-type="media"} on Figshare). The CpG (cg09180262) was significant only for Model 3 with small effect size (− 0.0002 per log unit CRP). We also assessed "the extremes" by comparing newborn methylation in infants born to women consistently in the highest tertile of CRP (*n* = 64) for all 3 trimesters of pregnancy compared to newborns of women consistently at the lowest tertile (*n* = 62). In this analysis, DNA methylation levels at 5 CpGs were associated with CRP, the most highly associated CpG being in the intron of the major histocompatibility complex, class II, DQ beta 1 (*HLA-DQB1*). See Supplemental Table [3](#MOESM1){ref-type="media"} for annotated results of the top 6 CpGs and [Supplemental Tables D--E](#MOESM1){ref-type="media"} on Figshare for full results.

In the analysis comparing newborn CRP measured in cord blood at the same time as DNA methylation, 108 significant associations were observed in crude models (Model 1) without cell-type adjustment initially in EAGeR. After Model 2 adjustment using the Bakulski reference \[[@CR21]\] to estimate cell type distribution, 71 significant associations were found. This number was further reduced in Model 3 after adjustment for cell type as estimated by Gervin et al. \[[@CR22]\], and 33 significant associations were identified (Table [4](#Tab4){ref-type="table"}). Supplemental Figure [2](#MOESM1){ref-type="media"} shows the overlap in the associations found between the 3 models. Of all the CpGs identified, 20 were FDR-significant in all three models regardless of cell type adjustment, whereas 6 associations (as marked by asterisks in Table [4](#Tab4){ref-type="table"}) were significant only in Model 3. Effect sizes of Model 3 associations ranged from 2 to 15% differences in methylation per log unit change in CRP at delivery, and the top 8 CpGs were Bonferroni significant (*p* \< 6 × 10^−8^). There were almost equal numbers of CpGs that had higher methylation (18 CpGs) as lower methylation (15 CpGs) in relation to increasing concentrations of CRP at delivery. The top CpG (cg13138089, *p* = 2 × 10^−14^) is in the CpG island for the gene *ECEL1P2* (Endothelin Converting Enzyme Like 1 Pseudogene 2), which is relevant for endothelial function. Apart from the 3 CpGs on the X chromosome, 3 associated with non-coding RNAs, and 4 with no known genes within 5 kb, the gene locations and functions of the remaining 23 CpGs were reviewed ([Supplemental Text](#MOESM1){ref-type="media"}). Among the 33 significant CpGs, no significant cell type specific signals were identified by eFORGE. However, enrichment for transcription factors related to immune cell lineages preserved across evolutionary lines was noted from several databases (Supplemental Figure [3](#MOESM1){ref-type="media"} and Supplemental Table [4](#MOESM1){ref-type="media"}). Table 4Delivery CRP and newborn DNA methylation in EAGeRCpGBetaSE*p* valueFDR *p* valuechrposGene nameRelation to island\*\*cg131380890.1520.019882.11E−141.73E−082233251770*ECEL1P2*Islandcg23289135− 0.12530.017314.63E−131.90E−07176182962OpenSeacg023233560.052830.0088982.89E−090.000652220313153*SPEG*Islandcg18875674− 0.071960.012153.19E−090.000651173026651*ARHGEF17*OpenSeacg135587540.092360.015724.22E−090.000691936247867*HSPB6; PROSER3*Islandcg16426346− 0.098360.017068.14E−090.001161377047N_Shorecg20789824− 0.029130.0052793.42E−080.0049127562861*OLFML2A*OpenSeacg17990365− 0.049330.0090364.79E−080.004911319718*IFITM3*S_Shorecg108843410.022920.0042336.16E−080.00562198365065*HSPE1*Islandcg202647320.024380.0045448.05E−080.00661668269763*ESRP2*Islandcg19013417− 0.022860.0043131.17E−070.0087X6146809*NLGN4X*S_Shorecg19922333− 0.040850.0078061.66E−070.0112218253142*DIRC3*OpenSeacg24340661− 0.022550.0043672.43E−070.0121166944531*MAEL; ILDR2*N_Shorecg17238334− 0.031590.006112.33E−070.012571920983LINC02056OpenSeacg23200634− 0.091060.017632.39E−070.0121168709832*IGHMBP2*OpenSeacg04415152\*0.039670.007642.08E−070.01211119383197USP2-AS1OpenSeacg12615852− 0.067560.012971.92E−070.012614106330121N_Shelfcg124998720.061910.01213.09E−070.0141658019893*TEPP*Islandcg02660803− 0.096080.018853.44E−070.015X91033070*PCDH11X*N_Shorecg231330110.031350.0061763.84E−070.01611122847242*BSX*N_Shorecg254608070.040840.0080974.55E−070.018821908022*DMTN*S_Shelfcg184499640.034820.0069254.94E−070.0181872917101*ZADH2*Islandcg25389127− 0.014820.0029987.62E−070.027X8700496ANOS1Islandcg228766430.035350.0071979.06E−070.03168962318*DEPDC1*Islandcg04136921− 0.054920.011219.67E−070.03115626314*TRIM6; TRIM6-TRIM34*OpenSeacg263541280.03250.0066369.72E−070.031493897195*UNC79*Islandcg19766763\*0.03070.0062478.93E−070.031861604237*SERPINB10*Islandcg19561181\*− 0.052470.01081.17E−060.032056794558*ANKRD60*OpenSeacg10235275\*0.035520.0073981.58E−060.041065225544*JMJD1C*Islandcg09689461\*0.06010.01261.84E−060.0481163130728*LOC101928404; RGS5*OpenSeacg033055850.03390.0071051.83E−060.048737805796OpenSeacg21542650\*0.031610.006631.87E−060.048122903593*FKBP4*Islandcg189739390.034440.0072351.94E−060.048204347116164122*FLJ37453*IslandModel 3 adjusted for maternal age, smoking status, income, pre-pregnancy BMI, plate, and cell count distribution (as estimated in Gervin et al. \[[@CR22]\])Asterisk (\*) indicates CpG not previously identified in previous crude models or model 1 adjusting for cell type using Balkulski et al. \[[@CR21]\]Double asterisks (\*\*) as defined by Illumina \[[@CR23]\]

Lastly, approximately half of the EAGeR participants were randomized to low-dose aspirin as expected (Table [1](#Tab1){ref-type="table"}). Randomization to low dose aspirin was not associated with differences in newborn methylation (Supplemental Figure [1](#MOESM1){ref-type="media"}), except for DNA methylation at one CpG (cg2002882, chromosome 13, position 79169823, beta = 0.009, FDR-*p* = 0.04).

Discussion {#Sec3}
==========

We report, to our knowledge, the first study to examine the longitudinal association between prenatal inflammation as repeatedly measured by CRP and newborn DNA methylation at delivery (Supplemental Figure [4](#MOESM1){ref-type="media"}). Associations relevant to inflammation/angiogenesis were identified in newborns at delivery suggesting that CRP, as an acute phase reactant, associates with methylation of circulating cells when measured at the same time point, reiterating CRP's role in inflammatory and angiogenic pathways although the temporality of these associations remains unclear. Few associations in genes related to histocompatibility proteins/antigens were identified with persistent high CRP.

CRP during pregnancy {#Sec4}
--------------------

The general lack of association between circulating maternal CRP levels during pregnancy and newborn DNA methylation may be related to several reasons. First, due to its short half-life, CRP may represent transient acute inflammation rather than chronic inflammation. However, few associations emerged even when we modeled longitudinal CRP levels in two different ways to capture women with relatively and chronically higher levels throughout pregnancy. These analyses were done by modeling cumulative CRP using an area under the curve model with repeated measures and by categorizing women consistently in the top tertile of CRP from first through third trimester. For the latter, we observed a few differences in DNA methylation located at genes related to immune function after cell type adjustment. *HLA-DQB1* codes for a class II major histocompatibility complex protein, *PUM3* codes for a minor histocompatibility antigen, and *MYO1G* codes for a minor histocompatibility antigen precursor. In other studies evaluating prenatal exposures on offspring methylation, *HLA-DQB1* methylation differed between siblings at 4--6 years of age before and after maternal weight loss from bariatric surgery \[[@CR24]\], and *MYO1G* methylation was associated with environmental chemical exposure \[[@CR25]\]. However, these findings require replication given the selectiveness of the sample.

As CRP does not cross the placental barrier \[[@CR26]\], its indirect influence on neonatal health may be modified by downstream factors including immune responses. And while the majority of previous studies have found maternal CRP to be associated with smaller newborn size \[[@CR27], [@CR28]\], it is inconsistently associated with other conditions \[[@CR2], [@CR29]\]. Studies linking maternal CRP with childhood asthma/allergies \[[@CR12], [@CR14]\] have also been inconsistent. These observations, in combination with the natural rise of CRP during pregnancy \[[@CR30]\], make it difficult to evaluate normative rather than "elevated" CRP in the context of pregnancy. We modeled linear associations with the understanding that higher inflammation is indicative of cellular damage, but in the context of pregnancy, it is possible that some non-linear relationships exist for the lowest and the highest CRP levels. Second, CRP levels have been shown not to correlate with other cytokines measured early in pregnancy \[[@CR31]\]. Thus, other biomarkers that may provide a fuller picture of prenatal inflammation may be needed to further investigate the role of inflammation. Third, cord blood CRP levels were 10- to 20-fold lower than maternal CRP levels (Table [2](#Tab2){ref-type="table"}), despite evidence that maternal CRP increases dramatically during labor and delivery \[[@CR32]\]. Placental production of CRP is largely directed into maternal circulation \[[@CR33]\]. Thus, natural protective mechanisms may cause maternal CRP to not reflect local inflammation in the developing fetus and explains why it is not associated with newborn methylation. Last, the sample size of EAGeR (*n* = 391) has limited power to detect differences. Nevertheless, a meta-analysis of over 1600 newborns and the findings for CRP at delivery in EAGeR suggest otherwise. Taken together, maternal CRP levels during pregnancy are generally not associated with alterations in DNA methylation patterns to the offspring as measured at delivery in cord blood.

Randomization to low-dose aspirin was also largely not associated with differences in newborn methylation. The single association identified on chromosome 13 (cg20028827) after accounting for multiple testing (FDR *p* = 0.04) was located \~ 3.5 kb upstream of the promoter of *POU4F1* (chr13:79173227-79177695). It is in a DNase hypersensitive site (chr13:79169325-79170815) with peaks for transcription factors EZH2 and SUZ12, among others. The levels of H2K4Me1 are slightly higher but with no apparent enhancer overlap. However, the CpG is within the intron of several ncRNA variants of the OBI1-AS1 (previously known as the PUF1-AS1 or RNF219-AS1). A log unit increase in CRP levels was associated with a \< 1% increase in methylation levels (adjusted beta = 0.009). *POU4F1* codes for neural transcriptors, particular to ganglions, by playing a role in development of calcium channels \[[@CR34]\]. However, its methylation has only been examined with regard to breast tissue tumors (where it was found to be hypermethylated and its expression silenced) \[[@CR35]\].

CRP at delivery {#Sec5}
---------------

While no associations with maternal CRP were identified, newborn CRP levels were associated with differences in cord blood methylation. Interestingly, 13 of the CpGs were located in or near genes associated with inflammatory or angiogenic pathways (*ECEL1P2*, *SPEG*, *ARHGEF17*, *OLFML2A*, *HSPB6*, *HSPE1*, *IFITM3*, *ZADH2*, *DEPDC1*, *TRIM6*, *SERPINB10*, *JMJD1C*, and *RGS5*). Of note, the top 7 genes, 5 of which exceeded Bonferroni significance, are among these genes. eFORGE results also confirm these methylation changes corresponded to transcription factors involved in development of immune cell lineages. These observations further support their biological relevance in relation to CRP. Previous studies that have measured inflammation and methylation in adults have been systematically reviewed \[[@CR36]\]. We compared the cross-sectional associations found in the current analysis at birth with those of previous epigenome-wide association studies among adults but were unable to find overlap between statistically significant CpGs identified by other studies and our results \[[@CR17], [@CR18]\]. All but one study used the 450K panel, such that most of the identified CpGs in the current analysis are unique. We add to the list of CpGs identified, which include sites that are novel to the EPIC microarray. Myte et al. also used the EPIC microarray but had a limited sample size of \< 200 adults \[[@CR18]\]. Cord blood samples unlike those from older children or adults normally contain nucleated red blood cells, which may also explain differences among studies \[[@CR37]\]. Moreover, immune system development continues after delivery as the newborn comes into contact with microbes, whereas adult immune systems have matured with respect to a range of environmental exposures and their own microbiome \[[@CR38]\].

Limitations {#Sec6}
-----------

EAGeR included women with 1--2 previous pregnancy losses. We cannot exclude that genetic causes of pregnancy loss \[[@CR39]\], including a role for CRP \[[@CR40]\], may play a role. This may limit the generalizability of the EAGeR results. However, the PACE birth cohorts contributing to the first trimester analysis were recruited from the general population and echoed the same findings with regards to maternal CRP. The small sample size of EAGeR and the meta-analysis may have limited power to detect weaker associations. Given that inflammation plays an integral role in recruitment of white blood cells, using a mix of cells as in buffy coat or any blood sample without prior selection of cell type for DNA methylation measurement requires estimation of cell type based on previous reference panels \[[@CR21], [@CR22]\]. Remaining estimation errors cannot be excluded. Also, the specificity of the associations identified to CRP is unclear. Our results are based on cord blood derived methylation and unclear if generalizable to other tissues. CRP is just one acute phase protein (APP), and various cytokines/chemokines either leading to APP production are increased by APPs (e.g., interleukins, TNF-a) in turn recruits immune cells. Thus, associations might have been due to correlated cytokine production and upstream factors. Lastly, the Illumina platform covers a large number of CpG sites but only a small fraction of the genome. It might not provide sufficient coverage to evaluate differences in global methylation as other techniques \[[@CR41]\]. Nevertheless, site specific differences identified in this approach revealed specific genes and biological pathways related to inflammation.

Conclusion {#Sec7}
----------

In conclusion, DNA methylation levels as measured in cord blood do not correlate with prenatal levels of CRP over pregnancy. Rather, methylation levels are consistent with concurrently measured CRP. The differentially methylated CpG sites suggest pathways that are modulated by inflammatory cytokines. Future research in larger studies and using different biomarkers of inflammation apart from CRP are needed for understanding the role of prenatal inflammation in fetal and neonatal developmental programming. Other epigenetic mechanisms such as histone acetylation and non-coding RNAs may also provide insights into the role of prenatal inflammation.

Methods {#Sec8}
=======

Study design {#Sec9}
------------

The Effects of Aspirin in Gestation and Reproduction (EAGeR) trial (2007--2011; NCT00467363) randomized women prior to conception who previously experienced 1--2 prior pregnancy losses to 81 mg low-dose aspirin and 400 μg folic acid, or placebo plus 400 μg folic acid \[[@CR42]\]. Randomization to low-dose aspirin did not significantly alter live birth rates \[[@CR42]\]. Its design and results are detailed elsewhere \[[@CR42]\]. The current analysis was nested among 391 newborns with DNA methylation data available from the Utah site \[[@CR43]\]. The University of Utah IRB approved the study (Salt Lake City, Utah IRB \#1002521), and all participants provided written informed consent prior to enrollment. Among the 391 newborns with methylation data, we excluded 12 newborns of non-white self-reported ethnicity (to avoid population stratification in meta-analysis across cohorts) and 9 for missing CRP measures.

Laboratory methods {#Sec10}
------------------

Women in EAGeR underwent multiple blood draws; first at baseline prior to pregnancy and at approximately 8, 20, and 36 weeks gestation during pregnancy. In addition, among 428 deliveries from the Utah site, 10 mL cord blood was collected in a plasma collection tube with ethylenediaminetetraacetic acid (EDTA) \[[@CR43]\]. CRP was quantified from maternal serum samples and cord blood plasma by means of an immunoturbidimetric assay (Roche COBAS 6000, Roche Diagnostics, IN) with a limit of detection (LOD) of 0.15 mg/L. Cord blood DNA underwent bisulphite conversion with standardized kits (e.g. Zymo EZ DNA MethylationTM kit, Zymo, Irvine, CA), followed by measurements of DNA methylation using the Infinium MethylationEPIC BeadChip microarray \[[@CR43]\].

Statistical analysis {#Sec11}
====================

Data cleaning for EAGeR {#Sec12}
-----------------------

Methylation data were processed using the minfi package in R \[[@CR44]\], including the identification of failed probes and scaling with Illumina control probes to determine methylation values. The beta value (*β*) was determined for each of the CpG sites by the fluorescent signals (*β* = Max (*M*, 0) / \[Max (*M*, 0) + Max (*U*, 0) + 100), where *M* and *U* are the intensity of methylated and unmethylated allele \[[@CR45]\]. *β* values approaching 1 are completely methylated, and those close to 0 are unmethylated. Background and dye-bias corrections were applied. Quantile normalization was used to normalize beta values between two types of probes \[[@CR46]\]. The purpose of this step is to eliminate potential probe type bias (type I vs II probes). Cell type mixture was then estimated on the full set of normalized data (FlowSorted.CordBlood.450K package) \[[@CR21]\]. Principal component analysis (PCA) was performed to further detect outliers and samples mismatched in sex compared against information from electronic medical records. Five samples with sex mismatch were further excluded. We extracted the detection *p* value for each methylation measure (per site per sample) and filtered data that failed detection *p* value (*p* \> 0.01). Beta values were replaced as missing if either detection *p* value \> 0.01 or bead counts \< 3. We removed samples and CpG sites with low passing rate (\< 97%) based on detection *p* value and bead counts. After probe removal, 821,665 CpG probes remained.

Modeling exposure for EAGeR {#Sec13}
---------------------------

To exclude acute inflammation from infection, maternal and cord plasma samples with CRP above 10 mg/L were excluded from analysis (15 at preconception, 39 at 8 weeks, 54 at 20 weeks, 28 at 36 weeks, 1 at delivery from EAGeR). Among the 391 neonates with DNA methylation data, 358 remained for analyses with CRP measured at any time during pregnancy. CRP was natural log transformed for normality. Longitudinal measures were also used in combination to examine inflammation in two ways. First, the cumulative concentration of CRP (log transformed) across the first, second, and third trimesters was approximated using linear mixed models. The linear mixed model was fitted with a random intercept and random centered week of CRP measurements. The model estimates also incorporated fixed effects including an intercept and a linear and quadratic term of centered week of CRP measurements, based on the regression curve of the original CRP concentrations. For each subject, parameters from the model were used to define the predicted CRP curves. The area below the curves was divided into 1000 parts. The area of each part was then calculated as a rectangle, since they are very small, and summed to obtain the cumulative CRP concentrations over pregnancy \[[@CR47]\]. In addition, methylation was also examined by comparing two extreme groups of women that is women in the top tertile of CRP across all trimesters were compared with women in the bottom tertile across all trimesters. Cumulative and tertile analyses did not exclude maternal CRP levels above 10 mg/L to better characterize inflammation across the whole of pregnancy for the same woman. While the primary analysis excluded CRP levels above 10 to rule out outliers that would have strong influence on estimates based on linear regression models, it would have excluded too many women for cumulative or tertile analyses who just had one of the 3 with an "elevated" measure. The cumulative and tertile analyses were more robust to outlying CRP.

Modeling outcomes for EAGeR {#Sec14}
---------------------------

Trimming of the outlying methylation values at IQR ± 3 × IQR (IQR = inter-quartile range) was performed after values were normalized. Complete case analyses were performed without imputation. Linear mixed effects models were used to test associations between methylation beta values at each CpG site and measured CRP at each time point and as cumulative or by extreme tertiles with adjustment for covariates. Batch effects (as covariates of chip and row) were accounted for through random effects. FDR-correction was applied to account for multiple testing.

Covariates for EAGeR {#Sec15}
--------------------

Covariates included maternal age (continuous, by self-report), smoking (yes/no by self-report), income (5 categories from ≥ \$100,000, \$75,000--99,999, \$40,000--69,999, \$20,000--19,999, ≤ \$19,999 by self-report), pre-pregnancy BMI (continuous, by direct measure prior to pregnancy), plate (for batch effects), and with or without cell count distribution (in separate models). Rather than adjustment for self-reported ethnicity, 12 non-white participants were excluded from EAGeR analyses. Three models were run; Model 1 adjusting for covariates and two models additionally adjusting for cell type distribution using two separate reference panels. Model 2 adjusted for covariates and cell counts based on a cord blood reference using *minfi* in R \[[@CR21]\], including B-cell, CD-4+ T cells, CD-8+ T cells, granulocytes, monocytes, NK-cells, and nucleated RBCs. A major difference previously identified between adult and cord blood cell count distribution in terms of DNA contribution from buffy coat samples is the proportion of nucleated red blood cells \[[@CR21]\]. Model 3 used a more recent cord blood reference pooling together larger number of samples with available cell distribution information \[[@CR22]\].

Meta-analysis {#Sec16}
-------------

As part of the PACE consortium \[[@CR20]\], three pregnancy cohorts (INMA \[[@CR48]\], Generation R \[[@CR49]\], PREDO \[[@CR50]\]) provided results for the associations between CRP measured in first trimester samples and DNA methylation measured in cord blood at delivery adjusting for the covariates mentioned above including with and without adjustment for cell type using two different references as described above \[[@CR21], [@CR22]\]. A meta-analysis of results was conducted with EAGeR as the fourth cohort. Inverse-variance weighted fixed effects meta-analysis was performed among a total of 1603 newborns using the software METAL \[[@CR51]\]. Specific analytical and laboratory methods are included in Supplemental materials for each of the cohorts.

Bioinformatics {#Sec17}
--------------

All FDR-significant CpGs were searched in the UCSC Genome Browser for genes within 5 kb of the location provided by Illumina. Information on distance to the TSS or which region within a gene body the CpG is located was ascertained. Gene names were further updated using the NCBI Gene Database. To further understand functional enrichment, eFORGE (v2.0) was utilized \[[@CR52]\].
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